Nuclidium closes CHF 105M Series B to advance radiopharmaceuticals
What's the deal? Swiss radiopharmaceutical company Nuclidium has closed a CHF 26M extension to its Series B round, bringing the total raise to CHF 105M (approx. EUR 115M). The Basel-based company, which develops copper-based radiotheranostics for targeted cancer treatment and diagnosis, announced the closing as it continues to build out its pipeline and technology platform.
Why now? Radiopharmaceuticals — drugs that deliver radioactive isotopes directly to cancer cells — have become one of the hottest areas in biotech investing. Large pharma companies have been snapping up radiopharma assets at premium valuations, creating strong tailwinds for earlier-stage players like Nuclidium.
The signal: The extension signals sustained investor confidence in the radiopharma space, even as broader biotech funding remains selective. Nuclidium's ability to top up an already sizable Series B suggests demand for its approach outpaced the original round's allocation — a sign that the sector's momentum is far from peaking.
Read more: nuclidium.com
